Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EpiBrentlen: Brentuximab Vedotin + Lenalidomide in Lymphoma
NCT03302728Phase 1Completed
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- Aug 2018
- Primary completion
- Aug 2021
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of brentuximab vedotin and lenalidomide in Hodgkin lymphoma (HL), peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL), sponsored by Peter MacCallum Cancer Centre. Primary endpoint: Maximum Tolerated Dose at 70 weeks. Started Aug 2018; status: completed.
02
Drugs
brentuximab vedotinlenalidomide
03
Conditions
Hodgkin lymphoma (HL)peripheral T-cell lymphoma (PTCL)cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT03302728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03302728.